Anti-obesity drugs assist in weight management by suppressing appetite and inhibiting fat absorption. They provide an alternative to bariatric surgeries for individuals suffering from obesity and overweight conditions. Containing the twin epidemics of obesity and diabetes has become a major priority, leading to higher adoption of anti-obesity medications in clinical practice. The global Anti-Obesity Drug Market is estimated to be valued at US$ 2542 Mn in 2023 and is expected to exhibit a CAGR of 20% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:

The increased uptake of anti-obesity treatment can be attributed to growing awareness and focus on obesity management. Healthcare providers are actively screening and monitoring obesity indicators like BMI to identify at-risk patients. Moreover, availability of new drug formulations targeting different obesity pathways has expanded treatment options. Drugs suppressing appetite through 5-HT2C receptor agonism or blocking fat absorption in the gut are emerging as effective alternatives to lifestyle modification alone. As obesity-related comorbidities place a huge burden on healthcare systems, treatment guidelines now recommend a combination of diet, physical activity and FDA-approved anti-obesity pharmacotherapy to facilitate long-term weight control and management of co-existing conditions like diabetes and cardiovascular disease.

Segment Analysis

The global anti-obesity drug market is dominated by weight loss drugs segment. This segment accounts for over 35% of the market share as weight loss drugs help in reducing appetite and absorption of fat in the body. They have less side effects when compared with other options such as bariatric surgery.

Key Takeaways

The Global Anti-Obesity Drug Market Size is expected to witness high growth. The global Anti-Obesity Drug Market is estimated to be valued at US$ 2542 Mn in 2023 and is expected to exhibit a CAGR of 20% over the forecast period 2023 to 2030.

North America is expected to remain the largest and fastest growing regional market for anti-obesity drugs during the forecast period. High obesity rates and strong presence of key players are major factors driving the market in the region.

Key players operating in the anti-obesity drug market are GE Healthcare, R1 RCM, Inc. (Accretive Health), Allscripts Healthcare Solutions, Inc., Kareo, Inc., Cerner Corporation, Quest Diagnostics, and Experian Information Solutions, Inc., among others. Major players are continuously focusing on new product development and introduction of generic drugs to increase their market share.
Get More Insights Here

https://healthcarelatesteditionnews.blogspot.com/2023/12/the-global-anti-obesity-drug-market.html